FDA Reduces Advisory Meetings Amid Controversial Decisions
The FDA is cutting back on public advisory committee meetings as contested drug approval decisions mount, raising transparency concerns for patients nationwide.
Public Health Correspondent
Priya Patel is an epidemiologist at the Hawaii Department of Health with expertise in disease surveillance, vaccination programs, and public health policy. She holds a doctorate in epidemiology from Johns Hopkins Bloomberg School of Public Health and reports on population-level health data for Hawaii Medical Journal.
The FDA is cutting back on public advisory committee meetings as contested drug approval decisions mount, raising transparency concerns for patients nationwide.